Trevigen致力于为研究人员提供高品质的试剂和试剂盒，用于细胞程序性死亡、DNA损伤和修复的研究。在过去的十年里，对于凋亡的研究越来越多，然而直到最近才开始将凋亡与DNA损伤联系在一起，并给予极大的关注。Trevigen能够为这一新兴领域提供高水平的产品和支持。而基于Trevigen在肿瘤研究产品核心业务的自然延伸，Trevigen开发出了一系列用于研究肿瘤细胞功能和行为的产品，包括血管生成、细胞侵袭、浸润和肿瘤形成等产品和试剂盒。所有Trevigen品牌的产品均基于最高质量标准生产，并被给予最强有力的技术支持。

Trevigen, Inc. is an innovative biotechnology company focused on the development of products and technology for cancer research and genetic toxicology, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. The company is located in the I-270 “Technology Corridor” in Gaithersburg, Maryland. Trevigen-brand research products are marketed via the Internet, journal advertising, direct mail, and telemarketing, giving Trevigen worldwide recognition among those in the area of cancer research. Distributor appointments have been made in the Americas, Europe, and the Pacific Rim. Trevigen also has in place supply agreements with major government and university medical research centers in order to make us a part of the growing areas of government research and pharmaceutical research. The company is the recipient of several SBIR grants from the National Institutes of Health, concerning technology development for the analysis of DNA damage.

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com

艾美捷科技代理EliteCell品牌。

EliteCell公司在细胞培养添加物市场拥有超过10年的丰富cGMP制造经验，专注于开发细胞疗法研究和商业开发的先进解决方案。EliteCell与美国获得FDA许可，并于AABB认证的血液中心合作，提供100％可追溯的产品。EliteCell公司致力于为细胞治疗行业和研究提供安全有效的细胞培养产品。

艾美捷科技特约代理BioPorto Diagnostics A/S公司产品。

BioPorto Diagnostics A/S公司成立于2001年，是丹麦一家专门生产抗体和基于抗体的各种生物产品的公司。BioPorto拥有Bioporto Diagnostics和Antibodyshop两个品牌，分别侧重于诊断试剂盒和抗体产品。在30多个国家有代理商，产品销售网络遍布全球，99%以上为出口销售。BioPorto Diagnostics旗下产品主要为几种临床快速诊断试剂盒，包括诊断早期急性肾损伤的NGAL ELISA kit，Gc-globulin ELISA kit ，评估原发性免疫缺陷的MBL Oligomer ELISA kit，同时还有相关其他种属的科研用试剂盒和抗原抗体。其最新推出的产品有检测人体血浆中的活性蛋白C-蛋白C抑制物(APC-PCI)复合物的APC-PCI ELISA kit，高纯度人IgE单克隆抗体，以及Glucagon-like peptide-1和Exendin-4相关的单抗。

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.